SMYD2

N-lysine methyltransferase SMYD2 · Q9NRG4 · SMYD2 on Sugi Atlas →

12,862 patent compounds predicted against SMYD2, 3,786 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3590884	1.00	12/20
SCHEMBL3591752	0.83	12/20
SCHEMBL3589383	0.82	12/20
Trifluoroacetic Acid (SCHEMBL3587227)	0.78	12/20
Trifluoroacetic Acid (SCHEMBL3590575)	0.78	12/20
SCHEMBL3585853	0.76	12/20
Trifluoroacetic Acid (SCHEMBL3590515)	0.74	12/20
SCHEMBL2209815	0.65	12/20
SCHEMBL1558651	0.60	12/20
SCHEMBL3585717	0.57	12/20
Trifluoroacetic Acid (SCHEMBL1559417)	0.57	12/20
SCHEMBL3586044	0.56	12/20
SCHEMBL2036625	0.52	12/20
SCHEMBL2213494	0.61	11/20
SCHEMBL3590391	0.57	11/20
SCHEMBL3590610	0.54	11/20
SCHEMBL3584341	0.54	11/20
SCHEMBL3590889	0.51	11/20
Trifluoroacetic Acid (SCHEMBL3586140)	0.51	11/20
Trifluoroacetic Acid (SCHEMBL3587100)	0.51	11/20

Clinical trials — most relevant to SMYD2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation	PHASE2	UNKNOWN
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia	PHASE2	RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)	PHASE1	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD	nan	NOT_YET_RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Genetic Study of Familial Factors in Patients With Colon Cancer	nan	COMPLETED
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
MEHMO Natural History and Biomarkers	nan	RECRUITING
Smurf2 Gene Expression in Urinary Tract Tumors	nan	UNKNOWN
COPENHAGEN Minipuberty Study	nan	UNKNOWN
MD2, Cystatin C and DNA Methylation Tags as Serum Biomarkers for POCD.	nan	UNKNOWN
Mechanisms of Immune Deficiency	nan	UNKNOWN
Hydroxymethylation, Incident Type 2 Diabetes and Incident Obesity	nan	UNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Identifying Methylation Biomarkers for Monitoring Bladder Tumors	nan	UNKNOWN
Investigation of the Genetic and Environmental Causes of Autism: a Multi-Center Study	nan	NOT_YET_RECRUITING
Natural History Study of Smith-Magenis Syndrome	nan	ACTIVE_NOT_RECRUITING
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy	nan	RECRUITING
Methylation of DNA in Children and Adolescents With Type 1 Diabetes Mellitus (METHYLDIAB)	nan	COMPLETED
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Adenosylmethionine Metabolism in Human Inflammation	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SMYD2 binder may also engage these)

Protein	Name	Similarity
C3RZA1	—	1.000	C3RZA1 →
Q0P585	—	1.000	Q0P585 →
Q8R5A0	—	1.000	Q8R5A0 →
Q7M6Z3	—	1.000	Q7M6Z3 →
Q6GN68	—	1.000	Q6GN68 →
Q7ZXV5	—	1.000	Q7ZXV5 →
E1C5V0	—	0.999	E1C5V0 →
SMYD3	Histone-lysine N-methyltransferase SMYD3	0.989	landscape →
Q9CWR2	—	0.988	Q9CWR2 →
Q5BJI7	—	0.988	Q5BJI7 →
Q8NB12	—	0.986	Q8NB12 →
P97443	—	0.984	P97443 →
Q5RGL7	—	0.978	Q5RGL7 →
Q8BTK5	—	0.970	Q8BTK5 →
Q3TYX3	—	0.970	Q3TYX3 →
O94952	—	0.969	O94952 →
Q5R5S1	—	0.968	Q5R5S1 →
RIOX2	Ribosomal oxygenase 2	0.968	landscape →
P98192	—	0.968	P98192 →
E1BMP7	—	0.967	E1BMP7 →
PRMT9	Protein arginine N-methyltransferase 9	0.967	landscape →
Q3UR70	—	0.966	Q3UR70 →
Q5R5X9	—	0.966	Q5R5X9 →
Q8IYR2	—	0.966	Q8IYR2 →
Q9LDC0	—	0.966	Q9LDC0 →
Q8NHP6	—	0.965	Q8NHP6 →
A6QQ71	—	0.965	A6QQ71 →
Q8VDH1	—	0.965	Q8VDH1 →
Q8WUH2	—	0.965	Q8WUH2 →
B3DNN5	—	0.964	B3DNN5 →